$1.98 Billion is the total value of Rock Springs Capital Management LP's 149 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -1,296,568 | -100.0% | -0.03% | – |
VRX | Exit | VALEANT PHARMACEUTICALS INTL | $0 | – | -66,400 | -100.0% | -0.04% | – |
NVCR | Exit | NOVOCURE LTD | $0 | – | -214,316 | -100.0% | -0.10% | – |
CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.16% | – |
LGND | Exit | LIGAND PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.30% | – |
NBRV | Exit | NABRIVA THERAPEUTICS AGsponsored adr | $0 | – | -525,000 | -100.0% | -0.36% | – |
ATHN | Exit | ATHENAHEALTH INC | $0 | – | -62,750 | -100.0% | -0.41% | – |
EVHC | Exit | ENVISION HEALTHCARE CORP | $0 | – | -145,000 | -100.0% | -0.51% | – |
PTHN | Exit | PATHEON N V | $0 | – | -400,000 | -100.0% | -0.61% | – |
AMGN | Exit | AMGEN INC | $0 | – | -98,000 | -100.0% | -0.93% | – |
SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -138,900 | -100.0% | -1.40% | – |
LLY | Exit | LILLY ELI & CO | $0 | – | -325,000 | -100.0% | -1.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
INVITAE CORP | 35 | Q3 2023 | 1.8% |
BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
MACROGENICS INC | 35 | Q3 2023 | 0.5% |
COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-05-01 |
SC 13G/A | 2024-04-05 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.